Pharmaceuticals

The journey from brand launch to retail shelf has shrunk from years to just 18 months. A new playbook reveals how TikTok data and GLP-1 drugs are the forces behind this massive shift.

Sumitomo Pharma's new data reveals a potent combination therapy for myelofibrosis and decodes resistance in leukemia, shaking up a competitive oncology landscape.

The financial giant extends its massive Security and Resiliency Initiative north, targeting defense, energy, and supply chains to bolster regional stability.

A new precision drug, ART5803, is offering hope for a devastating brain disorder. Arialys Therapeutics is fast-tracking its development with key clinical trials.

A 23% national drop in overdose deaths signals progress, but regional disparities and a volatile drug supply show the fight is far from over.

Facing a 'going concern' warning and collapsing revenue, Splash Beverage Group is ditching drinks for drugs. Its investment in Avicanna is a desperate, yet strategic, pivot.

New data reveals elevated cortisol in over 75% of hard-to-treat diabetes patients, paving the way for a novel drug to tackle treatment resistance.

A new study offers hope for MS by promoting nerve repair, but the real story is the validation of a versatile stem cell platform for a new era of medicine.

With a landmark therapy for Sanfilippo Syndrome nearing the FDA, Spruce adds veteran marketing and finance chiefs. A look at the talent behind the transition.

While CEO Craig Chambliss's EY award makes headlines, the real story is Neurelis's disruption of epilepsy care and its ambitious pipeline for brain disorders.

Phase 1 data for Marea Therapeutics’ MAR002 suggests a potential new era for acromegaly treatment, promising better control with far fewer injections.

A new, single-shot vaccine for dogs targets two spreading diseases. This innovation aims to make vet visits less stressful and close critical health gaps.

Amid new Ebola fears, one biotech's rapid C1 platform promises 15-day biologics, eyeing a $25B market beyond just pandemic response. But can it deliver?

As 250 million people await a drug for lymphatic diseases, Celltaxis appoints a new CEO to drive its promising inflammation-targeting therapy toward the finish line.

A missed clinical trial endpoint is often the end. For Elicio Therapeutics, a deeper data dive reveals a potential path forward for a high-need patient group.

Tiziana Life Sciences’ chairman just increased his massive stake. We analyze if this is a vote of confidence in its novel MS drug or a risky bet on a fragile biotech.

New data reveals an oral drug can halt severe hereditary angioedema attacks in minutes, promising a future free from needles and fear for thousands.

A new partnership between Argonaut and Ensera aims to untangle complex supply chains for drug-device products, potentially leveling the field for smaller innovators.

A small Canadian firm's breakthrough in water technology could slash energy use in major industries. But can it overcome the hurdles to commercialization?

For 20 years, Montreal's Segal Cancer Centre has quietly built a world-class innovation engine. We dissect its unique model where research, care, and funding converge.